Naltrexone Explained

Verifiedfields:verified
Watchedfields:verified
Verifiedrevid:464372546
Width:200
Width2:250
Tradename:Revia, Vivitrol, Depade, others
Dailymedid:Naltrexone
Pregnancy Au:B3
Routes Of Administration:By mouth, intramuscular injection, subcutaneous implant
Atc Prefix:N07
Atc Suffix:BB04
Legal Au:S4
Legal Au Comment:[1]
Legal Br:C1
Legal Br Comment:[2]
Legal Ca:Rx-only
Legal Uk:POM
Legal Us:Rx-only
Legal Status:Rx-only
Bioavailability:5–60%
Protein Bound:20%
Metabolism:Liver (non-CYP450)[3]
Metabolites:6β-Naltrexol, others
Onset:30 minutes
Elimination Half-Life:Oral (Revia):[4]
• Naltrexone: 4 hours
• 6β-Naltrexol: 13 hours
Oral (Contrave):[5]
• Naltrexone: 5 hours
(Vivitrol):[6]
• Naltrexone: 5–10 days
• 6β-Naltrexol: 5–10 days
Duration Of Action:>72 hours
Excretion:Urine
Cas Number:16590-41-3
Pubchem:5360515
Iuphar Ligand:1639
Drugbank:DB00704
Chemspiderid:4514524
Unii:5S6W795CQM
Kegg:D05113
Chebi:7465
Chembl:19019
Synonyms:EN-1639A; UM-792; ALKS-6428; N-cyclopropylmethylnoroxymorphone; N-cyclopropylmethyl-14-hydroxydihydromorphinone; 17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Iupac Name:(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one
C:20
H:23
N:1
O:4
Smiles:O=C4[C@@H]5Oc1c2c(ccc1O)C[C@H]3N(CC[C@]25[C@@]3(O)CC4)CC6CC6
Stdinchi:1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1
Stdinchikey:DQCKKXVULJGBQN-XFWGSAIBSA-N
Melting Point:169

Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use or opioid use disorder by reducing cravings and feelings of euphoria associated with substance use disorder. It has also been found effective in the treatment of other addictions and may be used for them off-label. An opioid-dependent person should not receive naltrexone before detoxification. It is taken by mouth or by injection into a muscle. Effects begin within 30 minutes, though a decreased desire for opioids may take a few weeks to occur.

Side effects may include trouble sleeping, anxiety, nausea, and headaches. In those still on opioids, opioid withdrawal may occur. Use is not recommended in people with liver failure. It is unclear if use is safe during pregnancy.[7] Naltrexone is an opioid antagonist and works by blocking the effects of opioids, including both opioid drugs as well as opioids naturally produced in the brain.[8]

Naltrexone was first made in 1965 and was approved for medical use in the United States in 1984.[8] [9] Naltrexone, as naltrexone/bupropion (brand name Contrave), is also used to treat obesity.[10] It is on the World Health Organization's List of Essential Medicines.[11] In 2021, it was the 254th most commonly prescribed medication in the United States, with more than 1million prescriptions.[12] [13]

Medical uses

Alcohol use disorder

Naltrexone has been best studied as a treatment for alcoholism.[14] Naltrexone has been shown to decrease the quantity and frequency of ethanol consumption by reducing the dopamine release from the brain after consuming alcohol.[15] [16] [17] It does not appear to change the percentage of people drinking.[18] Its overall benefit has been described as "modest".[19] [20]

Acamprosate may work better than naltrexone for eliminating alcohol abuse, while naltrexone may decrease the desire for alcohol to a greater extent.[21]

A method pioneered by scientist John David Sinclair (dubbed commercially the “Sinclair Method”) advocates for “pharmacological extinction” of problem drinking behavior by administering naltrexone alongside controlled alcohol consumption. In effect, he argues naltrexone induced opiate antagonism sufficiently disrupts reflexive reward mechanisms inherent in the consumption of alcohol and, given enough repetition, will disassociate positive associations formerly made with the consumption of alcohol. The Sinclair Method has a clinically proven success rate of 78%.[22]

Opioid use

Long-acting injectable naltrexone (under the brand name Vivitrol) is an opioid receptor antagonist, blocking the effects of heroin and other opioids, and decreases heroin use compared to a placebo.[23] Unlike methadone and buprenorphine, it is not a controlled medication.[23] It may decrease cravings for opioids after a number of weeks, and decreases the risk of overdose, at least during the time period that naltrexone is still active, though concern about risk of overdose for those stopping treatment remains.[8] [24] It is given once per month and has better compliance and effect for opioid use than the oral formulation.[25]

A drawback of injectable naltrexone is that it requires patients with opioid use disorder and current physiological dependence to be fully withdrawn before it is initiated to avoid a precipitated opioid withdrawal that may be quite severe. In contrast, initiation of buprenorphine only requires delay of the first dose until the patient begins to manifest at least mild opioid withdrawal symptoms.[26] Among patients able to successfully initiate injectable naltrexone, long-term remission rates were similar to those seen in clinical buprenorphine/naloxone administration.[27]

Consequence of relapse when weighting best course of treatment for opiate use disorder remains a concern. Methadone and buprenorphine administration maintains greater drug tolerance while naltrexone allows tolerance to fade, leading to higher instances of overdose in people who relapse and thus higher mortality. World Health Organization guidelines state that most patients should be advised to use opioid agonists (e.g., methadone or buprenorphine) rather than opioid antagonists like naltrexone, citing evidence of superiority in reducing mortality and retaining patients in care.[28]

A 2011 review found insufficient evidence to determine the effect of naltrexone taken by mouth in opioid dependence.[29] While some do well with this formulation, it must be taken daily, and a person whose cravings become overwhelming can obtain opioid intoxication simply by skipping a dose. Due to this issue, the usefulness of oral naltrexone in opioid use disorders is limited by the low retention in treatment. Naltrexone by mouth remains an ideal treatment for a small number of people with opioid use, usually those with a stable social situation and motivation. With additional contingency management support, naltrexone may be effective in a broader population.[30]

Others

Unlike varenicline (brand name Chantix), naltrexone is not useful for quitting smoking.[31] Naltrexone has also been under investigation for reducing behavioral addictions such as gambling, NSSID (non suicidal self injury disorder) and kleptomania as well as compulsive sexual behaviors in both offenders and non-offenders (e.g. compulsive porn viewing and masturbation). The results were promising. In one study, the majority of sexual offenders reported a strong reduction in sexual urges and fantasies which reverted to baseline once the medication was discontinued. Case reports have also shown cessation of gambling and other compulsive behaviors, for as long as the medication was taken.[32] [33]

When taken at much smaller doses, a regimen known as low-dose naltrexone (LDN), naltrexone may reduce pain and help to address neurological symptoms. Some patients report that LDN helps reduce their symptoms of ME/CFS, multiple sclerosis (MS), fibromyalgia (FMS), or autoimmune disease. Although its mechanism of action is unclear, some have speculated that it may act as an anti-inflammatory.[34] LDN is also being considered as a potential treatment for long COVID.[35]

Available forms

See also: Bupropion/naltrexone, Morphine/naltrexone and Buprenorphine/naltrexone.

Naltrexone is available and most commonly used in the form of an oral tablet (50 mg). Vivitrol, a naltrexone formulation for depot injection containing 380 mg of the medication per vial, is also available.[36] Additionally, naltrexone subcutaneous implants that are surgically implanted are available.[37] While these are manufactured in Australia, they are not authorized for use within Australia, but only for export.[38] By 2009, naltrexone implants showed superior efficacy in the treatment of heroin dependence when compared to the oral form.[39]

Contraindications

Naltrexone should not be used by persons with acute hepatitis or liver failure, or those with recent opioid use (typically 7–10 days).

Side effects

The most common side effects reported with naltrexone are gastrointestinal complaints such as diarrhea and abdominal cramping. These adverse effects are analogous to the symptoms of opioid withdrawal, as the μ-opioid receptor blockade will increase gastrointestinal motility.

The side effects of naltrexone by incidence are as follows:

Opioid withdrawal

Naltrexone should not be started until several (typically 7–10) days of abstinence from opioids have been achieved. This is due to the risk of acute opioid withdrawal if naltrexone is taken, as naltrexone will displace most opioids from their receptors. The time of abstinence may be shorter than 7 days, depending on the half-life of the specific opioid taken. Some physicians use a naloxone challenge to determine whether an individual has any opioids remaining. The challenge involves giving a test dose of naloxone and monitoring for opioid withdrawal. If withdrawal occurs, naltrexone should not be started.[40]

Adverse effects

Whether naltrexone causes dysphoria, depression, anhedonia, or other aversive effects as side effects has been studied and reviewed.[41] [42] [43] [44] In early studies of normal and opioid-abstinent individuals, acute and short-term administration of naltrexone was reported to produce a variety of aversive effects including fatigue, loss of energy, sleepiness, mild dysphoria, depression, lightheadedness, faintness, mental confusion, nausea, gastrointestinal disturbances, sweating, and occasional feelings of unreality.[45] [46] [47] [48] However, these studies were small, often uncontrolled, and used subjective means of assessing side effects. Most subsequent longer-term studies of naltrexone for indications like alcohol or opioid dependence have not reported dysphoria or depression with naltrexone in most individuals.[43] [49] According to one source:

Naltrexone itself produces little or no psychoactive effect in normal research volunteers even at high doses, which is remarkable given that the endogenous opioid system is important in normal hedonic functioning. Because endogenous opioids are involved in the brain reward system, it would be reasonable to hypothesize that naltrexone might produce anhedonic or dysphoric effects. Although some evidence from small, early trials suggested that patients with a history of opiate dependence might be susceptible to dysphoric effects in response to naltrexone (Crowley et al. 1985; Hollister et al. 1981), reports of such effects have been inconsistent. Most large clinical studies of recovering opioid-dependent individuals have not found naltrexone to have an adverse effect on mood (Greenstein et al. 1984; Malcolm et al. 1987; Miotto et al. 2002; Shufman et al. 1994). Some studies have actually found improvements in mood during the course of treatment with naltrexone (Miotto et al. 1997; Rawlins and Randall 1976).

Based on available evidence, naltrexone seems to have minimal untoward effects in the aforementioned areas, at least with long-term therapy. It has been suggested that differences in findings between acute and longer-term studies of naltrexone treatment might be related to altered function in the opioid system with chronic administration of naltrexone. For example, marked upregulation of opioid receptors and hyper-sensitivity to opioids have been observed with naltrexone in preclinical studies.[50] Another possibility is that the central opioid system may have low endogenous functionality in most individuals, becoming active only in the presence of exogenously administered opioid receptor agonists or with stimulation by endogenous opioids induced by pain or stress. A third possibility is that normal individuals may experience different side effects with naltrexone than people with addictive disease such as alcohol or opioid dependence, who may have altered opioid tone or responsiveness. It is notable in this regard that most studies of naltrexone have been in people with substance dependence.

Naltrexone may also initially produce opioid withdrawal-like symptoms in a small subset of people not dependent on opioids:[51]

The side-effect profile [of naltrexone], at least on the recommended dose of 50 mg per day, is generally benign, although 5 to 10 percent of detoxified opioid addicts experience immediate, intolerable levels of withdrawal-like effects including agitation, anxiety, insomnia, light-headedness, sweating, dysphoria, and nausea. Most patients on naltrexone experience few or no symptoms after the first 1 to 2 weeks of treatment; for a substantial minority (20 to 30 percent) protracted discomfort is experienced.

Persisting affective distress related to naltrexone may account for individuals taking the drug who drop out of treatment.[52]

Naltrexone has been reported to reduce feelings of social connection.[53] [54] [55] [56] The μ-opioid receptor has been found to play a major role in social reward in animals and the μ-opioid receptor knockout mouse is an animal model of autism.[57] Studies on whether naltrexone can decrease the pleasurable effects of listening to music are conflicting.[58] [59] [60] Besides humans, naltrexone has been found to produce aversive effects in rodents as assessed by conditioned place aversion.

Liver damage

Naltrexone has been reported to cause liver damage when given at doses higher than recommended. It carries an FDA boxed warning for this rare side effect. Due to these reports, some physicians may check liver function tests prior to starting naltrexone, and periodically thereafter. Concerns for liver toxicity initially arose from a study of nonaddicted obese patients receiving 300 mg of naltrexone.[61] Subsequent studies have suggested limited or no toxicity in other patient populations and at typical recommended doses such as 50 to 100 mg/day.

Overdose

No toxic effects have been observed with naltrexone in doses of up to 800 mg/day in clinical studies. The largest reported overdose of naltrexone, which was 1,500 mg in a female patient and was equivalent to an entire bottle of medication (30 × 50 mg tablets), was uneventful.[62] No deaths are known to have occurred with naltrexone overdose.[63]

Pharmacology

Pharmacodynamics

Opioid receptor blockade

Naltrexone at human opioid receptors
Affinities Ratios Refs
MOR:KOR:DOR
1.0 nM 3.9 nM 149 nM 1:4:149 [64]
0.0825 nM 0.509 nM 8.02 nM 1:6:97 [65]
0.2 nM 0.4 nM 10.8 nM 1:2:54 [66] [67]
0.23 nM 0.25 nM 38 nM 1:1.1:165 [68] [69]
0.62 nM 1.88 nM 12.3 nM 1:3:20 [70] [71]
0.11 nM 0.19 nM 60 nM 1:1.7:545 [72] [73] [74]

Naltrexone and its active metabolite 6β-naltrexol are competitive antagonists of the opioid receptors. Naltrexone is specifically an antagonist preferentially of the μ-opioid receptor (MOR), to a lesser extent of the κ-opioid receptor (KOR), and to a much lesser extent of the δ-opioid receptor (DOR).[75] However, naltrexone is not actually a silent antagonist of these receptors but instead acts as a weak partial agonist, with Emax values of 14 to 29% at the MOR, 16 to 39% at the KOR, and 14 to 25% at the DOR in different studies.[76] In accordance with its partial agonism, although naltrexone is described as a pure opioid receptor antagonist, it has shown some evidence of weak opioid effects in clinical and preclinical studies.

By itself, naltrexone acts as an antagonist or weak partial agonist of the opioid receptors. In combination with agonists of the MOR such as morphine however, naltrexone appears to become an inverse agonist of the MOR. Conversely, naltrexone remains a neutral antagonist (or weak partial agonist) of the KOR and DOR. In contrast to naltrexone, 6β-naltrexol is purely a neutral antagonist of the opioid receptors. The MOR inverse agonism of naltrexone when it is co-present with MOR agonists may in part underlie its ability to precipitate withdrawal in opioid-dependent individuals.[77] This may be due to suppression of basal MOR signaling via inverse agonism.

Occupancy of the opioid receptors in the brain by naltrexone has been studied using positron emission tomography (PET). Naltrexone at a dose of 50 mg/day has been found to occupy approximately 90 to 95% of brain MORs and 20 to 35% of brain DORs.[78] Naltrexone at a dose of 100 mg/day has been found to achieve 87% and 92% brain occupancy of the KOR in different studies.[79] [80] [81] Per simulation, a lower dose of naltrexone of 25 mg/day might be expected to achieve around 60% brain occupancy of the KOR but still close to 90% occupancy of the MOR. In a study of the duration of MOR blockade with naltrexone, the drug with a single 50 mg dose showed 91% blockade of brain [<sup>11</sup>C]carfentanil (a selective MOR ligand) binding at 48 hours (2 days), 80% blockade at 72 hours (3 days), 46% blockade at 120 hours (5 days), and 30% blockade at 168 hours (7 days).[82] [83] The half-time of brain MOR blockade by naltrexone in this study was 72 to 108 hours (3.0 to 4.5 days). Based on these findings, doses of naltrexone of even less than 50 mg/day would be expected to achieve virtually complete brain MOR occupancy. Blockade of brain MORs with naltrexone is much longer-lasting than with other opioid antagonists like naloxone (half-time of ~1.7 hours intranasally) or nalmefene (half-time of ~29 hours).[84] [85]

The half-life of occupancy of the brain MOR and duration of clinical effect of naltrexone are much longer than suggested by its plasma elimination half-life.[86] [87] A single 50 mg oral dose of naltrexone has been found to block brain MORs and opioid effects for at least 48 to 72 hours.[88] The half-time of brain MOR blockade by naltrexone (72–108 hours) is much longer than the fast plasma clearance component of naltrexone and 6β-naltrexol (~4–12 hours) but was reported to correspond well to the longer terminal phase of plasma naltrexone clearance (96 hours). As an alternative possibility, the prolonged brain MOR occupancy by opioid antagonists like naltrexone and nalmefene may be due to slow dissociation from MORs consequent to their very high MOR affinity (<1.0 nM).[89]

Naltrexone blocks the effects of MOR agonists like morphine, heroin, and hydromorphone in humans via its MOR antagonism. Following a single 100 mg dose of naltrexone, the subjective and objective effects of heroin were blocked by 90% at 24 hours, with blockade then decreasing up to 72 hours. Similarly, 20 to 200 mg naltrexone dose-dependently antagonized the effects of heroin for up to 72 hours. Naltrexone also blocks the effects of KOR agonists like salvinorin A, pentazocine, and butorphanol in humans via its KOR antagonism.[90] [91] [92] In addition to opioids, naltrexone has been found to block or reduce the rewarding and other effects of other euphoriant drugs including alcohol, nicotine,[93] and amphetamines.[94]

The opioid receptors are involved in neuroendocrine regulation. MOR agonists produce increases in levels of prolactin and decreases in levels of luteinizing hormone (LH) and testosterone. Doses of naltrexone of 25 to 150 mg/day have been found to produce significant increases in levels of β-endorphin, cortisol, and LH, equivocal changes in levels of prolactin and testosterone, and no significant changes in levels of adrenocorticotrophic hormone (ACTH) or follicle-stimulating hormone (FSH). Naltrexone influences the hypothalamic–pituitary–adrenal axis (HPA axis) probably through interference with opioid receptor signaling by endorphins.

Blockade of MORs is thought to be the mechanism of action of naltrexone in the management of opioid dependence—it reversibly blocks or attenuates the effects of opioids. It is also thought to be involved in the effectiveness of naltrexone in alcohol dependence by reducing the euphoric effects of alcohol. The role of KOR modulation by naltrexone in its effectiveness for alcohol dependence is unclear but this action may also be involved based on theory and animal studies.[95] [96]

Other activities

In addition to the opioid receptors, naltrexone binds to and acts as an antagonist of the opioid growth factor receptor (OGFR) and toll-like receptor 4 (TLR4) and interacts with high- and low-affinity binding sites in filamin A (FLNA).[97] [98] [99] [100] It is said that very low doses of naltrexone (<0.001–1 mg/day) interact with FLNA, low doses (1 to 5 mg/day) produce TLR4 antagonism, and standard clinical doses (50 to 100 mg/day) exert opioid receptor and OGFR antagonism. The interactions of naltrexone with FLNA and TLR4 are claimed to be involved in the therapeutic effects of low-dose naltrexone.

Pharmacokinetics

Absorption

The absorption of naltrexone with oral administration is rapid and nearly complete (96%). The bioavailability of naltrexone with oral administration is 5 to 60% due to extensive first-pass metabolism.[101] Peak concentrations of naltrexone are 19 to 44 μg/L after a single 100 mg oral dose and time to peak concentrations of naltrexone and 6β-naltrexol (metabolite) is within 1 hour. Linear increases in circulating naltrexone and 6β-naltrexol concentrations occur over an oral dose range of 50 to 200 mg. Naltrexone does not appear to be accumulated with repeated once-daily oral administration and there is no change in time to peak concentrations with repeated administration.

Distribution

The plasma protein binding of naltrexone is about 20% over a naltrexone concentration range of 0.1 to 500 μg/L. Its apparent volume of distribution at 100 mg orally is 16.1 L/kg after a single dose and 14.2 L/kg with repeated doses.

Metabolism

Naltrexone is metabolized in the liver mainly by dihydrodiol dehydrogenases into 6β-naltrexol (6β-hydroxynaltrexone). Levels of 6β-naltrexol are 10- to 30-fold higher than those of naltrexone with oral administration due to extensive first-pass metabolism.[102] Conversely, 6β-naltrexol exposure is only about 2-fold higher than that of naltrexone with intramuscular injection of naltrexone in microspheres (brand name Vivitrol). 6β-Naltrexol is an opioid receptor antagonist similarly to naltrexone and shows a comparable binding profile to the opioid receptors.[103] However, 6β-naltrexol is peripherally selective and crosses into the brain much less readily than does naltrexone. In any case, 6β-naltrexol does still show some central activity and may contribute significantly to the central actions of oral naltrexone.[50] Other metabolites of naltrexone include 2-hydroxy-3-methoxy-6β-naltrexol and 2-hydroxy-3-methoxynaltrexone. Following their formation, the metabolites of naltrexone are further metabolized by conjugation with glucuronic acid to form glucuronides. Naltrexone is not metabolized by the cytochrome P450 system and has low potential for drug interactions.

Elimination

The elimination of naltrexone is biexponential and rapid over the first 24 hours followed by a third extremely slow decline after 24 hours. The fast elimination half-lives of naltrexone and its metabolite 6β-naltrexol are about 4 hours and 13 hours, respectively. In Contrave oral tablets, which also contain bupropion and are described as extended-release, the half-life of naltrexone is 5 hours. The slow terminal-phase elimination half-life of naltrexone is approximately 96 hours. As microspheres of naltrexone by intramuscular injection (Vivitrol), the elimination half-lives of naltrexone and 6β-naltrexol are both 5 to 10 days. Whereas oral naltrexone is administered daily, naltrexone in microspheres by intramuscular injection is suitable for administration once every 4 weeks or once per month.

Naltrexone and its metabolites are excreted in urine.

Pharmacogenetics

Tentative evidence suggests that family history and presence of the Asn40Asp polymorphism predicts naltrexone being effective.[104] [20]

Chemistry

Naltrexone, also known as N-cyclopropylmethylnoroxymorphone, is a derivative of oxymorphone (14-hydroxydihydromorphinone). It is specifically the derivative of oxymorphone in which the tertiary amine methyl substituent is replaced with methylcyclopropane.

Analogues

The closely related medication, methylnaltrexone (N-methylnaltrexone), is used to treat opioid-induced constipation, but does not treat addiction as it does not cross the blood–brain barrier. Nalmefene (6-desoxy-6-methylenenaltrexone) is similar to naltrexone and is used for the same purposes as naltrexone. Naltrexone should not be confused with naloxone (N-allylnoroxymorphone), which is used in emergency cases of opioid overdose. Other opioid antagonists related to naltrexone include 6β-naltrexol (6β-hydroxynaltrexone), samidorphan (3-carboxamido-4-hydroxynaltrexone), β-funaltrexamine (naltrexone fumarate methyl ester), nalodeine (N-allylnorcodeine), nalorphine (N-allylnormorphine), and nalbuphine (N-cyclobutylmethyl-14-hydroxydihydronormorphine).

History

Naltrexone was first synthesized in 1963 by Metossian at Endo Laboratories, a small pharmaceutical company in New York City.[105] It was characterized by Blumberg, Dayton, and Wolf in 1965 and was found to be an orally active, long-acting, and very potent opioid antagonist.[106] [107] The drug showed advantages over earlier opioid antagonists such as cyclazocine, nalorphine, and naloxone, including its oral activity, a long duration of action allowing for once-daily administration, and a lack of dysphoria, and was selected for further development. It was patented by Endo Laboratories in 1967 under the developmental code name EN-1639A and Endo Laboratories was acquired by DuPont in 1969.[108] Clinical trials for opioid dependence began in 1973, and a developmental collaboration of DuPont with the National Institute on Drug Abuse for this indication started the next year in 1974. The drug was approved by the FDA for the oral treatment of opioid dependence in 1984, with the brand name Trexan, and for the oral treatment of alcohol dependence in 1995, when the brand name was changed by DuPont to Revia.[109] A depot formulation for intramuscular injection was approved by the FDA under the brand name Vivitrol for alcohol dependence in 2006 and opioid dependence in 2010.[109]

Society and culture

Generic names

Naltrexone is the generic name of the drug and its,,,, and, while naltrexone hydrochloride is its and .

Brand names

Naltrexone is or has been sold under a variety of brand names, including Adepend, Antaxone, Celupan, Depade, Nalorex, Narcoral, Nemexin, Nodict, Revia, Trexan, Vivitrex, and Vivitrol.[110] [111] [112] [113] It is also marketed in combination with bupropion (naltrexone/bupropion) as Contrave,[114] and was marketed with morphine (morphine/naltrexone) as Embeda.[115] A combination of naltrexone with buprenorphine (buprenorphine/naltrexone) has been developed, but has not been marketed.[116]

Controversies

The FDA authorized use of injectable naltrexone (Vivitrol) for opioid addiction using a single study[117] that was led by Evgeny Krupitsky at Bekhterev Research Psychoneurological Institute, St Petersburg State Pavlov Medical University, St Petersburg, Russia,[118] a country where opioid agonists such as methadone and buprenorphine are not available. The study was a "double-blind, placebo-controlled, randomized", 24-week trial running "from July 3, 2008, through October 5, 2009" with "250 patients with opioid dependence disorder" at "13 clinical sites in Russia" on the use of injectable naltrexone (XR-NTX) for opioid dependence. The study was funded by the Boston-based biotech Alkermes firm which produces and markets naltrexone in the United States. Critics charged that the study violated ethical guidelines, since it compared the formulation of naltrexone not to the best available, evidence-based treatment (methadone or buprenorphine), but to a placebo. Further, the trial did not follow patients who dropped out of the trial to evaluate subsequent risk of fatal overdose, a major health concern .[119] Subsequent trials in Norway and the US did compare injectable naltrexone to buprenorphine and found them to be similar in outcomes for patients willing to undergo the withdrawal symptoms required prior to naltrexone administration.[120] Nearly 30% of patients in the US trial did not complete induction.[27] In real world settings, a review of more than 40,000 patient records found that while methadone and buprenorphine reduced risk of fatal overdose, naltrexone administration showed no greater effect on overdose or subsequent emergency care than counseling alone.[121]

Despite these findings, naltrexone's manufacturer and some health authorities have promoted the medicine as superior to methadone and buprenorphine since it is not an opioid and does not induce dependence. The manufacturer has also marketed directly to law enforcement and criminal justice officials, spending millions of dollars on lobbying and providing thousands of free doses to jails and prisons. The technique has been successful, with the criminal justice system in 43 states now incorporating long-acting naltrexone. Many do this through Vivitrol courts that offer only this option, leading some to characterize this as "an offer that cannot be refused."[122] [123] The company's marketing techiques have led to a Congressional investigation,[124] and warning from the FDA about failure to adequately state risks of fatal overdose to patients receiving the medicine.[125]

In May 2017, United States Secretary of Health and Human Services Tom Price praised [Vivitrol] as the future of opioid addiction treatment after visiting the company's plant in Ohio. His remarks set off sharp criticism with almost 700 experts in the field of substance use submitting a letter to Price cautioning him about Vivitrol's "marketing tactics" and warning him that his comments "ignore widely accepted science".[126] The experts pointed out that Vivitrol's competitors, buprenorphine and methadone, are "less expensive", "more widely used", and have been "rigorously studied". Price had claimed that buprenorphine and methadone were "simply substitute[s]" for "illicit drugs"[127] whereas according to the letter, "the substantial body of research evidence supporting these treatments is summarized in guidance from within your own agency, including the Substance Abuse and Mental Health Services Administration, the US Surgeon General, the National Institute on Drug Abuse, and the Centers for Disease Control and Prevention. Buprenorphine and methadone have been demonstrated to be highly effective in managing the core symptoms of opioid use disorder, reducing the risk of relapse and fatal overdose, and encouraging long-term recovery."

Film

One Little Pill was a 2014 documentary film about use of naltrexone to treat alcohol use disorder.

Four Good Days is a 2020 film about the four days a drug addict woman has to stay sober to get a shot of naltrexone in a detox facility.

Research

Depersonalization

Naltrexone is sometimes used in the treatment of dissociative symptoms such as depersonalization and derealization.[128] [129] Some studies suggest it might help.[130] Other small, preliminary studies have also shown benefit. Blockade of the KOR by naltrexone and naloxone is thought to be responsible for their effectiveness in ameliorating depersonalization and derealization. Since these drugs are less efficacious in blocking the KOR relative to the MOR, higher doses than typically used seem to be necessary.

Low-dose naltrexone

Naltrexone has been used off-label at low doses for diseases not related to chemical dependency or intoxication, such as multiple sclerosis.[131] Evidence for recommending low-dose naltrexone is lacking.[132] [133] This treatment has received attention on the Internet.[134] In 2022, four studies (in a few hundred patients) were conducted on naltrexone for long COVID.[135]

Self-injury

One study suggests that self-injurious behaviors present in persons with developmental disabilities (including autism) can sometimes be remedied with naltrexone.[136] In these cases, the self-injury is believed to be done to release beta-endorphin, which binds to the same receptors as heroin and morphine.[137] If the "rush" generated by self-injury is removed, the behavior may stop.

Behavioral disorders

Some indications exist that naltrexone might be beneficial in the treatment of impulse-control disorders such as kleptomania, compulsive gambling, or trichotillomania (compulsive hair pulling), but evidence of its effectiveness for gambling is conflicting.[138] [139] A 2008 case study reported successful use of naltrexone in suppressing and treating an internet pornography addiction.[140]

Interferon alpha

Naltrexone is effective in suppressing the cytokine-mediated adverse neuropsychiatric effects of interferon alpha therapy.[141] [142]

Critical addiction studies

Some historians and sociologists have suggested that the meanings and uses attributed to anti-craving medicine, such as naltrexone, is context-dependent.[143] Studies have suggested the use of naltrexone in drug courts or healthcare rehabs is a form of "post-social control,"[144] or "post-disciplinary control,"[145] whereby control strategies for managing offenders and addicts shift from imprisonment and supervision toward more direct control over biological processes.

Sexual addiction

Small studies have shown a reduction of sexual addiction and problematic sexual behaviours from naltrexone.[146] [147]

Notes and References

  1. Web site: Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017 . Therapeutic Goods Administration (TGA) . 21 June 2022 . 30 March 2024.
  2. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  3. Book: Dean RL, Bilsky EJ, Negus SS . Opiate Receptors and Antagonists . Sevarino KA, Kosten TR . Naltrexone for Initiation and Maintenance of Opiate Abstinence . 2009 . 227–245 . Humana Press . 10.1007/978-1-59745-197-0_12 . 978-1-58829-881-2.
  4. Web site: Revia (naltrexone hydrochloride tablets USP50 mgOpioid Antagonist . DailyMed . 24 April 2015 . 13 June 2022 . 14 June 2022 . https://web.archive.org/web/20220614045520/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=172953 . live .
  5. Web site: Contrave Extended-Release – naltrexone hydrochloride and bupropion hydrochloride tablet, extended release . DailyMed . 4 November 2021 . 13 June 2022 . 4 June 2020 . https://web.archive.org/web/20200604190921/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b . live .
  6. Web site: Vivitrol- naltrexone kit . DailyMed . 10 March 2021 . 13 June 2022 . 30 May 2022 . https://web.archive.org/web/20220530151413/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd11c435-b0f0-4bb9-ae78-60f101f3703f . live .
  7. Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ . Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women . Pharmacotherapy . 37 . 7 . 824–839 . July 2017 . 28543191 . 10.1002/phar.1958 . 13772333 .
  8. Web site: Naltrexone Monograph for Professionals . Drugs.com. American Society of Health-System Pharmacists. 9 November 2017. live. https://web.archive.org/web/20171109134845/https://www.drugs.com/monograph/naltrexone.html. 9 November 2017.
  9. Book: Sadock BJ, Sadock VA, Sussman N . Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment. 2012. Lippincott Williams & Wilkins. 978-1451154467. 265. en. live. https://web.archive.org/web/20171205042100/https://books.google.ca/books?id=qp-H3UruKvIC&pg=PT265. 5 December 2017.
  10. . Naltrexone/bupropion for obesity . Drug and Therapeutics Bulletin . 55 . 11 . 126–129 . November 2017 . 29117992 . 10.1136/dtb.2017.11.0550 . 547660 .
  11. Book: ((World Health Organization)) . The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list . 2023 . 10665/371090 . World Health Organization . WHO . Geneva . WHO/MHP/HPS/EML/2023.02 . free .
  12. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  13. Web site: Naltrexone - Drug Usage Statistics . ClinCalc . 14 January 2024.
  14. Aboujaoude E, Salame WO . Naltrexone: A Pan-Addiction Treatment? . CNS Drugs . 30 . 8 . 719–733 . August 2016 . 27401883 . 10.1007/s40263-016-0373-0 . 6372144 .
  15. Spencer CN, Elton A, Dove S, Faulkner ML, Robinson DL, Boettiger CA . September 2023 . Naltrexone engages a brain reward network in the presence of reward-predictive distractor stimuli in males . Addiction Neuroscience . en . 7 . 100085 . 10.1016/j.addicn.2023.100085 . 37424633 . 10328541 . 257919116 . 2772-3925 .
  16. Spanagel R, Weiss F . The dopamine hypothesis of reward: past and current status . Trends in Neurosciences . 22 . 11 . 521–527 . November 1999 . 10529820 . 10.1016/s0166-2236(99)01447-2 . 35758115 .
  17. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M . Opioid antagonists for alcohol dependence . The Cochrane Database of Systematic Reviews . 12 . CD001867 . December 2010 . 21154349 . 10.1002/14651858.CD001867.pub2 . Srisurapanont M .
  18. Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C . The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis . Addiction . 110 . 6 . 920–930 . June 2015 . 25664494 . 10.1111/add.12875 . 15 April 2019 . live . https://web.archive.org/web/20190415034450/https://findings.org.uk/PHP/dl.php?file=Donoghue_K_1.txt&s=eb . 15 April 2019 .
  19. Garbutt JC . Efficacy and tolerability of naltrexone in the management of alcohol dependence . Current Pharmaceutical Design . 16 . 19 . 2091–2097 . 2010 . 20482515 . 10.2174/138161210791516459 .
  20. Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV . Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence . Addiction . 109 . 8 . 1274–1284 . August 2014 . 24661324 . 10.1111/add.12557 .
  21. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW . Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? . Addiction . 108 . 2 . 275–293 . February 2013 . 23075288 . 3970823 . 10.1111/j.1360-0443.2012.04054.x .
  22. Sinclair JD . 2001 . Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism . Alcohol and Alcoholism . 36 . 1 . 2–10 . 10.1093/alcalc/36.1.2 . 11139409 . free.
  23. Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O'Grady KE, Schwartz RP . Update on Barriers to Pharmacotherapy for Opioid Use Disorders . Current Psychiatry Reports . 19 . 6 . 35 . June 2017 . 28526967 . 7075636 . 10.1007/s11920-017-0783-9 .
  24. Sharma B, Bruner A, Barnett G, Fishman M . Opioid Use Disorders . Child and Adolescent Psychiatric Clinics of North America . 25 . 3 . 473–487 . July 2016 . 27338968 . 4920977 . 10.1016/j.chc.2016.03.002 .
  25. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP . Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial . Archives of General Psychiatry . 63 . 2 . 210–218 . February 2006 . 16461865 . 4200530 . 10.1001/archpsyc.63.2.210 .
  26. Shulman M, Wai JM, Nunes EV . Buprenorphine Treatment for Opioid Use Disorder: An Overview . CNS Drugs . 33 . 6 . 567–580 . June 2019 . 31062259 . 6585403 . 10.1007/s40263-019-00637-z .
  27. Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J . Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial . Lancet . 391 . 10118 . 309–318 . January 2018 . 29150198 . 5806119 . 10.1016/S0140-6736(17)32812-X .
  28. Book: Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence . 2009 . World Health Organization . 978-92-4-154754-3 . 28 September 2022 . 28 September 2022 . https://web.archive.org/web/20220928174406/https://www.who.int/publications/i/item/9789241547543 . live .
  29. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A . Oral naltrexone maintenance treatment for opioid dependence . The Cochrane Database of Systematic Reviews . 2011 . 4 . CD001333 . April 2011 . 21491383 . 7045778 . 10.1002/14651858.CD001333.pub4 . Minozzi S .
  30. Johansson BA, Berglund M, Lindgren A . Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review . Addiction . 101 . 4 . 491–503 . April 2006 . 16548929 . 10.1111/j.1360-0443.2006.01369.x .
  31. David SP, Lancaster T, Stead LF, Evins AE, Prochaska JJ . Opioid antagonists for smoking cessation . The Cochrane Database of Systematic Reviews . 6 . 6 . CD003086 . June 2013 . 23744347 . 4038652 . 10.1002/14651858.CD003086.pub3 .
  32. Mouaffak F, Leite C, Hamzaoui S, Benyamina A, Laqueille X, Kebir O . Naltrexone in the Treatment of Broadly Defined Behavioral Addictions: A Review and Meta-Analysis of Randomized Controlled Trials . European Addiction Research . 23 . 4 . 204–210 . 2017 . 28877518 . 10.1159/000480539 . free .
  33. Ryback RS . Naltrexone in the treatment of adolescent sexual offenders . The Journal of Clinical Psychiatry . 65 . 7 . 982–986 . July 2004 . 15291688 . 10.4088/jcp.v65n0715 .
  34. Web site: Low dose naltrexone . MEpedia . 24 September 2022 . 24 September 2022 . https://web.archive.org/web/20220924165641/https://me-pedia.org/wiki/Low_dose_naltrexone . live .
  35. O'Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS . Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study . Brain, Behavior, & Immunity – Health . 24 . 100485 . October 2022 . 35814187 . 9250701 . 10.1016/j.bbih.2022.100485 .
  36. "Web site: Alcoholism Once A Month Injectable Drug, Vivitrol, Approved By FDA . https://web.archive.org/web/20090105124047/http://www.medicalnewstoday.com/articles/41707.php . 5 January 2009 . Medical News Today . 16 April 2006 .
  37. Web site: Australian Register of Therapeutic Goods Medicines . 22 March 2009 . Therapeutic Goods Administration . Online database of approved medicines . live . https://web.archive.org/web/20090514095145/https://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuMedicines?OpenView . 14 May 2009 .
  38. Web site: Australian Register of Therapeutic Goods Medicines . 27 April 2017 . Therapeutic Goods Administration . Online database of approved medicines, specific entry for "O'Neil Long Acting Naltrexone Implant" .
  39. Hulse GK, Morris N, Arnold-Reed D, Tait RJ . Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone . Archives of General Psychiatry . 66 . 10 . 1108–1115 . October 2009 . 19805701 . 10.1001/archgenpsychiatry.2009.130 . free .
  40. Book: Galanter M, Kleber HD . The American Psychiatric Publishing Textbook of Substance Abuse Treatment . 2008 . American Psychiatric . 978-1-58562-276-4 .
  41. Miotto K, McCann M, Basch J, Rawson R, Ling W . Naltrexone and dysphoria: fact or myth? . The American Journal on Addictions . 11 . 2 . 151–160 . 2002 . 12028745 . 10.1080/10550490290087929 .
  42. Book: Strain EC, Stitzer ML . The Treatment of Opioid Dependence. 2006. JHU Press. 978-0-8018-8219-7. 296–. 2 June 2021. 2 June 2021. https://web.archive.org/web/20210602233938/https://books.google.com/books?id=timYFx278CUC&pg=PA296. live.
  43. Nathan PJ, O'Neill BV, Napolitano A, Bullmore ET . Neuropsychiatric adverse effects of centrally acting antiobesity drugs . CNS Neuroscience & Therapeutics . 17 . 5 . 490–505 . October 2011 . 21951371 . 6493804 . 10.1111/j.1755-5949.2010.00172.x .
  44. Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, Bushara N, Burakov A, Masalov D, Romanova T, Tyurina A, Palatkin V, Yaroslavtseva T, Pecoraro A, Woody G . Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant . The American Journal of Drug and Alcohol Abuse . 42 . 5 . 614–620 . September 2016 . 27436632 . 5156574 . 10.1080/00952990.2016.1197231 .
  45. Mendelson JH, Ellingboe J, Keuhnle JC, Mello NK . Effects of naltrexone on mood and neuroendocrine function in normal adult males . Psychoneuroendocrinology . 3 . 3–4 . 231–236 . October 1978 . 219434 . 10.1016/0306-4530(78)90013-6 . 7712730 .
  46. Hollister LE, Johnson K, Boukhabza D, Gillespie HK . Aversive effects of naltrexone in subjects not dependent on opiates . Drug and Alcohol Dependence . 8 . 1 . 37–41 . August 1981 . 7297411 . 10.1016/0376-8716(81)90084-3 .
  47. Crowley TJ, Wagner JE, Zerbe G, Macdonald M . Naltrexone-induced dysphoria in former opioid addicts . The American Journal of Psychiatry . 142 . 9 . 1081–1084 . September 1985 . 2992300 . 10.1176/ajp.142.9.1081 .
  48. Malcolm R, O'Neil PM, Von JM, Dickerson PC . Naltrexone and dysphoria: a double-blind placebo controlled trial . Biological Psychiatry . 22 . 6 . 710–716 . June 1987 . 3593812 . 10.1016/0006-3223(87)90202-2 . 39628172 .
  49. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA . The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking . Journal of Clinical Psychopharmacology . 26 . 6 . 610–625 . December 2006 . 17110818 . 10.1097/01.jcp.0000245566.52401.20 . 35171287 .
  50. Gonzalez JP, Brogden RN . Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence . Drugs . 35 . 3 . 192–213 . March 1988 . 2836152 . 10.2165/00003495-198835030-00002 . 195697174 .
  51. Rounsaville BJ . Can psychotherapy rescue naltrexone treatment of opioid addiction? . NIDA Research Monograph . 150 . 37–52 . 1995 . 8742771 . 31 October 2021 . live . https://web.archive.org/web/20220119134913/https://archives.drugabuse.gov/sites/default/files/monograph150.pdf#page=43 . 19 January 2022 .
  52. Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M . Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder . Drug and Alcohol Dependence . 192 . 264–270 . November 2018 . 30300800 . 6203294 . 10.1016/j.drugalcdep.2018.08.019 .
  53. Inagaki TK, Hazlett LI, Andreescu C . Opioids and social bonding: Effect of naltrexone on feelings of social connection and ventral striatum activity to close others . Journal of Experimental Psychology. General . 149 . 4 . 732–745 . April 2020 . 31414860 . 7021584 . 10.1037/xge0000674 .
  54. Inagaki TK, Hazlett LI, Andreescu C . Naltrexone alters responses to social and physical warmth: implications for social bonding . Social Cognitive and Affective Neuroscience . 14 . 5 . 471–479 . May 2019 . 30976797 . 6545530 . 10.1093/scan/nsz026 .
  55. Inagaki TK, Ray LA, Irwin MR, Way BM, Eisenberger NI . Opioids and social bonding: naltrexone reduces feelings of social connection . Social Cognitive and Affective Neuroscience . 11 . 5 . 728–735 . May 2016 . 26796966 . 4847702 . 10.1093/scan/nsw006 .
  56. Meier IM, Bos PA, Hamilton K, Stein DJ, van Honk J, Malcolm-Smith S . Naltrexone increases negatively-valenced facial responses to happy faces in female participants . Psychoneuroendocrinology . 74 . 65–68 . December 2016 . 27588701 . 10.1016/j.psyneuen.2016.08.022 . 1874/339404 . 40097592 . free .
  57. Oddi D, Crusio WE, D'Amato FR, Pietropaolo S . Monogenic mouse models of social dysfunction: implications for autism . Behav Brain Res . 251 . 75–84 . August 2013 . 23327738 . 10.1016/j.bbr.2013.01.002 .
  58. O'Brien CP, Gastfriend DR, Forman RF, Schweizer E, Pettinati HM . Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone . The American Journal on Addictions . 20 . 2 . 106–112 . 2011 . 21314752 . 3895092 . 10.1111/j.1521-0391.2010.00107.x .
  59. Mallik A, Chanda ML, Levitin DJ . Anhedonia to music and mu-opioids: Evidence from the administration of naltrexone . Scientific Reports . 7 . 1. 41952 . February 2017 . 28176798 . 5296903 . 10.1038/srep41952 . 2017NatSR...741952M .
  60. Laeng B, Garvija L, Løseth G, Eikemo M, Ernst G, Leknes S . 'Defrosting' music chills with naltrexone: The role of endogenous opioids for the intensity of musical pleasure . Consciousness and Cognition . 90 . 103105 . April 2021 . 33711654 . 10.1016/j.concog.2021.103105 . 232163311 .
  61. Pfohl DN, Allen JI, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE, Morley JE . Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage . NIDA Research Monograph . 67 . 66–72 . 1986 . 3092099 . dead . 23 January 2017 . https://web.archive.org/web/20170121150620/https://archives.drugabuse.gov/pdf/monographs/download67.html . 21 January 2017 .
  62. Reece AS . Clinical safety of 1500 mg oral naltrexone overdose . BMJ Case Reports . 2010 . sep06 1. bcr0420102871 . September 2010 . 22778191 . 3028212 . 10.1136/bcr.04.2010.2871 .
  63. Book: Miller PM . Interventions for Addiction . Pettinati HM, Dundon WD, Casares López MJ . Naltrexone and Opioid Antagonists for Alcohol Dependence . 2013 . 375–384 . Elsevier . 10.1016/B978-0-12-398338-1.00039-7 . 978-0-12-398338-1 .
  64. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T . Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors . Molecular Pharmacology . 45 . 2 . 330–334 . February 1994 . 8114680 . 22 June 2018 . live . 10.1.1.1076.4629 . . https://web.archive.org/web/20180622111441/http://molpharm.aspetjournals.org/content/45/2/330.short . 22 June 2018 .
  65. Codd EE, Shank RP, Schupsky JJ, Raffa RB . Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception . The Journal of Pharmacology and Experimental Therapeutics . 274 . 3 . 1263–1270 . September 1995 . 7562497 . 23 January 2017 . live . https://web.archive.org/web/20170202020241/http://jpet.aspetjournals.org/content/274/3/1263.short . 2 February 2017 .
  66. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS . Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications . NIDA Research Monograph . 178 . 440–466 . March 1998 . 9686407 . 10.1.1.475.3403 .
  67. Clark SD, Abi-Dargham A . The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence . Biological Psychiatry . 86 . 7 . 502–511 . October 2019 . 31376930 . 10.1016/j.biopsych.2019.05.012 . 162168648 . free .
  68. Peng X, Knapp BI, Bidlack JM, Neumeyer JL . Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors . Journal of Medicinal Chemistry . 50 . 9 . 2254–2258 . May 2007 . 17407276 . 3357624 . 10.1021/jm061327z .
  69. Unterwald EM . Naltrexone in the treatment of alcohol dependence . Journal of Addiction Medicine . 2 . 3 . 121–127 . September 2008 . 21768981 . 10.1097/ADM.0b013e318182b20f . 23603792 .
  70. Zheng MQ, Nabulsi N, Kim SJ, Tomasi G, Lin SF, Mitch C, Quimby S, Barth V, Rash K, Masters J, Navarro A, Seest E, Morris ED, Carson RE, Huang Y . Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging . Journal of Nuclear Medicine . 54 . 3 . 455–463 . March 2013 . 23353688 . 3775344 . 10.2967/jnumed.112.109512 .
  71. Cumming P, Marton J, Lilius TO, Olberg DE, Rominger A . A Survey of Molecular Imaging of Opioid Receptors . Molecules . 24 . 22 . 4190 . November 2019 . 31752279 . 6891617 . 10.3390/molecules24224190 . free .
  72. Wentland MP, Lu Q, Lou R, Bu Y, Knapp BI, Bidlack JM . Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone . Bioorganic & Medicinal Chemistry Letters . 15 . 8 . 2107–2110 . April 2005 . 15808478 . 10.1016/j.bmcl.2005.02.032 .
  73. Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, Ganorkar R, VanAlstine MA, Guo C, Cohen DJ, Bidlack JM . Syntheses of novel high affinity ligands for opioid receptors . Bioorganic & Medicinal Chemistry Letters . 19 . 8 . 2289–2294 . April 2009 . 19282177 . 2791460 . 10.1016/j.bmcl.2009.02.078 .
  74. Book: Dwoskin LP . 29 January 2014 . Emerging Targets and Therapeutics in the Treatment of Psychostimulant Abuse . Academic Press . 398– . 978-0-12-420177-4 . 1235841274 . 30 October 2021 . 27 April 2021 . https://web.archive.org/web/20210427142317/https://books.google.com/books?id=b3UpAgAAQBAJ&pg=PA398 . live .
  75. Niciu MJ, Arias AJ . Targeted opioid receptor antagonists in the treatment of alcohol use disorders . CNS Drugs . 27 . 10 . 777–787 . October 2013 . 23881605 . 4600601 . 10.1007/s40263-013-0096-4 .
  76. Wang D, Sun X, Sadee W . Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment . The Journal of Pharmacology and Experimental Therapeutics . 321 . 2 . 544–552 . May 2007 . 17267582 . 10.1124/jpet.106.118810 . 28500012 .
  77. Sadée W, Wang D, Bilsky EJ . Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities . Life Sciences . 76 . 13 . 1427–1437 . February 2005 . 15680308 . 10.1016/j.lfs.2004.10.024 .
  78. Ray LA, Chin PF, Miotto K . Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics . CNS & Neurological Disorders Drug Targets . 9 . 1 . 13–22 . March 2010 . 20201811 . 10.2174/187152710790966704 .
  79. Book: Placzek MS . The Kappa Opioid Receptor . Imaging Kappa Opioid Receptors in the Living Brain with Positron Emission Tomography . 271 . 547–577 . August 2021 . 34363128 . 10.1007/164_2021_498 . 978-3-030-89073-5 . Handbook of Experimental Pharmacology . Springer . Cham . 236947969 .
  80. de Laat B, Nabulsi N, Huang Y, O'Malley SS, Froehlich JC, Morris ED, Krishnan-Sarin S . Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving . Molecular Psychiatry . 26 . 9 . 5053–5060 . September 2021 . 32541931 . 10.1038/s41380-020-0811-8 . 219692020 .
  81. Vijay A, Morris E, Goldberg A, Petrulli J, Liu H, Huang Y, Krishnan-Sarin S . Naltrexone occupancy at kappa opioid receptors investigated in alcoholics by PET occupancy at kappa opioid receptors investigated in alcoholics by PET . Journal of Nuclear Medicine . 58 . Supplement 1 . 1 April 2017 . 1297 . 29 October 2021 . 29 October 2021 . https://web.archive.org/web/20211029050553/https://jnm.snmjournals.org/content/58/supplement_1/1297 . live .
  82. Book: Miller PM . Biological Research on Addiction . Comprehensive Addictive Behaviors and Disorders . 2 . Colasanti A, Lingford-Hughes A, Nutt D . Opioids Neuroimaging . 2013 . 675–687 . Elsevier . 10.1016/B978-0-12-398335-0.00066-2 . 9780123983350 .
  83. Lee MC, Wagner HN, Tanada S, Frost JJ, Bice AN, Dannals RF . Duration of occupancy of opiate receptors by naltrexone . Journal of Nuclear Medicine . 29 . 7 . 1207–1211 . July 1988 . 2839637 . 29 October 2021 . live . https://web.archive.org/web/20211029203041/https://jnm.snmjournals.org/content/29/7/1207.long . 29 October 2021 .
  84. Book: Dierckx RA, Otte A, de Vries EF, van Waarde A, Lammertsma AA . PET and SPECT of Neurobiological Systems . Waarde AV, Absalom AR, Visser AK, Dierckx RA . Positron Emission Tomography (PET) Imaging of Opioid Receptors . 30 September 2020 . 749–807 . Springer International Publishing . 10.1007/978-3-030-53176-8_21 . 978-3-030-53175-1 . 241535315 . https://pure.rug.nl/ws/files/349191745/978_3_030_53176_8.pdf . 21 May 2023 . 31 May 2023 . https://web.archive.org/web/20230531054330/https://pure.rug.nl/ws/files/349191745/978_3_030_53176_8.pdf . live .
  85. Soyka M, Rösner S . Nalmefene for treatment of alcohol dependence . Expert Opinion on Investigational Drugs . 19 . 11 . 1451–1459 . November 2010 . 20868291 . 10.1517/13543784.2010.522990 . 9227860 .
  86. Mannelli P, Peindl KS, Wu LT . Pharmacological enhancement of naltrexone treatment for opioid dependence: a review . Substance Abuse and Rehabilitation . 2011 . 2 . 113–123 . June 2011 . 21731898 . 3128868 . 10.2147/SAR.S15853 . free .
  87. Schuh KJ, Walsh SL, Stitzer ML . Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans . Psychopharmacology . 145 . 2 . 162–174 . July 1999 . 10463317 . 10.1007/s002130051045 . 5930936 .
  88. Book: Narcotic Antagonists: Naltrexone Pharmacochemistry and Sustained-release Preparations. 1981. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse, Division of Research. 148–. 2 June 2021. 2 June 2021. https://web.archive.org/web/20210602234451/https://books.google.com/books?id=HyVsAAAAMAAJ&pg=PA148. live.
  89. Ingman K, Hagelberg N, Aalto S, Någren K, Juhakoski A, Karhuvaara S, Kallio A, Oikonen V, Hietala J, Scheinin H . Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing . Neuropsychopharmacology . 30 . 12 . 2245–2253 . December 2005 . 15956985 . 10.1038/sj.npp.1300790 . 2453226 . free .
  90. Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, González M, Claramunt J, Barker S, Lomnicka I, Waguespack M, Johnson MW, Griffiths RR, Riba J . Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans . The International Journal of Neuropsychopharmacology . 19 . 7 . pyw016 . July 2016 . 26874330 . 4966277 . 10.1093/ijnp/pyw016 .
  91. Walsh SL, Chausmer AE, Strain EC, Bigelow GE . Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade . Psychopharmacology . 196 . 1 . 143–155 . January 2008 . 17909753 . 2766188 . 10.1007/s00213-007-0948-z .
  92. Preston KL, Bigelow GE . Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers . The Journal of Pharmacology and Experimental Therapeutics . 264 . 2 . 813–823 . February 1993 . 7679737 . 28 September 2022 . 28 November 2023 . https://web.archive.org/web/20231128061014/https://jpet.aspetjournals.org/content/264/2/813.long . live .
  93. Modesto-Lowe V, Van Kirk J . Clinical uses of naltrexone: a review of the evidence . Experimental and Clinical Psychopharmacology . 10 . 3 . 213–227 . August 2002 . 12233982 . 10.1037/1064-1297.10.3.213 .
  94. Lam L, Anand S, Li X, Tse ML, Zhao JX, Chan EW . Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials . Clinical Toxicology . 57 . 4 . 225–233 . April 2019 . 30451013 . 10.1080/15563650.2018.1529317 . 53951406 .
  95. Soyka M, Friede M, Schnitker J . Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis . Pharmacopsychiatry . 49 . 2 . 66–75 . March 2016 . 26845589 . 10.1055/s-0035-1565184 . 11540631 .
  96. Koob GF, Volkow ND . Neurobiology of addiction: a neurocircuitry analysis . The Lancet. Psychiatry . 3 . 8 . 760–773 . August 2016 . 27475769 . 6135092 . 10.1016/S2215-0366(16)00104-8 .
  97. Toljan K, Vrooman B . Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization . Medical Sciences . 6 . 4 . 82 . September 2018 . 30248938 . 6313374 . 10.3390/medsci6040082 . free .
  98. Bachtell R, Hutchinson MR, Wang X, Rice KC, Maier SF, Watkins LR . Targeting the Toll of Drug Abuse: The Translational Potential of Toll-Like Receptor 4 . CNS & Neurological Disorders Drug Targets . 14 . 6 . 692–699 . 2015 . 26022268 . 5548122 . 10.2174/1871527314666150529132503 .
  99. Lee B, Elston DM . The uses of naltrexone in dermatologic conditions . Journal of the American Academy of Dermatology . 80 . 6 . 1746–1752 . June 2019 . 30582992 . 10.1016/j.jaad.2018.12.031 . 58595160 .
  100. Zagon IS, Verderame MF, McLaughlin PJ . The biology of the opioid growth factor receptor (OGFr) . Brain Research. Brain Research Reviews . 38 . 3 . 351–376 . February 2002 . 11890982 . 10.1016/s0165-0173(01)00160-6 . 37812525 .
  101. Lee MW, Fujioka K . Naltrexone for the treatment of obesity: review and update . Expert Opinion on Pharmacotherapy . 10 . 11 . 1841–1845 . August 2009 . 19537999 . 10.1517/14656560903048959 . 207477935 . 10.1.1.496.9477 .
  102. Book: Davis MP, Glare PA, Hardy J. Opioids in Cancer Pain. 28 May 2009. Oxford University Press. 978-0-19-923664-0. 41–. 31 October 2021. 31 October 2021. https://web.archive.org/web/20211031063640/https://books.google.com/books?id=aEzg6i2nPMQC&pg=PA41. live.
  103. Book: 10.1016/S0065-7743(10)45009-5 . Opioid Receptor Antagonists for Gastrointestinal Dysfunction . Annual Reports in Medicinal Chemistry . 2010 . Hipkin RW, Dolle RE . 45 . 142–155 . Elsevier . 978-0-12-380902-5 .
  104. Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF . The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review . Alcoholism: Clinical and Experimental Research . 36 . 3 . 385–394 . March 2012 . 21895723 . 3249007 . 10.1111/j.1530-0277.2011.01633.x .
  105. Book: National Research Council (U.S.). Committee on Problems of Drug Dependence. Report of the Thirty-sixth Annual Scientific Meeting: Committee on Problems of Drug Dependence, Mexico City, March 10-14, 1974. 1974. National Academies. 265–. NAP:13963. 9780309022446. 4 December 2017. 27 April 2021. https://web.archive.org/web/20210427150422/https://books.google.com/books?id=pEYrAAAAYAAJ&pg=PA265. live.
  106. Book: Padwa HM, Cunningham J . Addiction: A Reference Encyclopedia. registration . 2010. ABC-CLIO. 978-1-59884-229-6. 207–.
  107. Book: Bennett G . Treating Drug Abusers. 14 January 2004. Routledge. 978-1-134-93173-6. 112–. 4 December 2017. 27 April 2021. https://web.archive.org/web/20210427160708/https://books.google.com/books?id=ft6IAgAAQBAJ&pg=PT112. live.
  108. Book: Wouk J . Google Ldn !. 1 March 2009. Lulu.com. 978-0-578-00439-6. 78–88. 4 December 2017. 28 April 2021. https://web.archive.org/web/20210428040328/https://books.google.com/books?id=9hOBAgAAQBAJ&pg=RA1-PA78. live.
  109. Book: Milhorn HT . Substance Use Disorders: A Guide for the Primary Care Provider. 17 October 2017. Springer International Publishing. 978-3-319-63040-3. 88–. 4 December 2017. 27 April 2021. https://web.archive.org/web/20210427131539/https://books.google.com/books?id=wH86DwAAQBAJ&pg=PA88. live.
  110. Book: Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 851–. 4 December 2017. 6 August 2020. https://web.archive.org/web/20200806230945/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA851. live.
  111. Book: Index Nominum 2000: International Drug Directory. 2000. Taylor & Francis. 978-3-88763-075-1. 715–. 4 December 2017. 6 August 2020. https://web.archive.org/web/20200806165935/https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA715. live.
  112. Book: Morton IK, Hall JM . Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 6 December 2012. Springer Science & Business Media. 978-94-011-4439-1. 189–.
  113. Web site: Naltrexone . 4 December 2017 . live . https://web.archive.org/web/20171204114601/https://www.drugs.com/international/naltrexone.html . 4 December 2017 .
  114. Web site: Bupropion and naltrexone Uses, Side Effects & Warnings . Drugs.com . 8 June 2020 . 16 September 2020 . 26 October 2020 . https://web.archive.org/web/20201026105451/https://www.drugs.com/mtm/bupropion-and-naltrexone.html . live .
  115. Web site: Morphine and naltrexone Uses, Side Effects & Warnings . Drugs.com . 14 October 2019 . 16 September 2020 . 25 October 2020 . https://web.archive.org/web/20201025230724/https://www.drugs.com/mtm/morphine-and-naltrexone.html . live .
  116. McCann DJ . Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders . Clinical Pharmacology and Therapeutics . 83 . 4 . 627–630 . April 2008 . 18212797 . 10.1038/sj.clpt.6100503 . 21165673 .
  117. Web site: A Shot in the Dark: Can Vivitrol Help Us Control Our Addictions?. Armstrong W . 7 May 2013. Pacific Standard. live. https://web.archive.org/web/20170913135050/https://psmag.com/social-justice/vivitrol-help-control-addictions-57261. 13 September 2017.
  118. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL . Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial . Lancet . 377 . 9776 . 1506–1513 . April 2011 . 21529928 . 10.1016/s0140-6736(11)60358-9 . 16690413 .
  119. 10.1016/S0140-6736(11)61333-0 . Injectable extended-release naltrexone for opioid dependence – Authors' reply . The Lancet . 378 . 9792 . 666 . 2011 . Wolfe D, Carrieri MP, Dasgupta N, Bruce D, Wodak A . 205963967 . free .
  120. Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N . Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial . JAMA Psychiatry . 74 . 12 . 1197–1205 . December 2017 . 29049469 . 6583381 . 10.1001/jamapsychiatry.2017.3206 .
  121. Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM . Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder . JAMA Network Open . 3 . 2 . e1920622 . February 2020 . 32022884 . 10.1001/jamanetworkopen.2019.20622 . 211035316 . free . 11143463 .
  122. Web site: MacGillis A . The Last Shot. 29 December 2021. ProPublica. en. 28 December 2021. https://web.archive.org/web/20211228162438/https://www.propublica.org/article/vivitrol-opiate-crisis-and-criminal-justice. live.
  123. Wolfe D, Saucier R . Biotechnologies and the future of opioid addiction treatments . The International Journal on Drug Policy . 88 . 103041 . February 2021 . 33246267 . 10.1016/j.drugpo.2020.103041 . 227191111 .
  124. Web site: Harper J . 7 November 2017. Kamala Harris Investigating Addiction Drug Manufacturer Alkermes. 29 December 2021. WFYI Public Media. en-us. 14 June 2022. https://web.archive.org/web/20220614045521/https://www.wfyi.org/news/articles/kamala-harris-investigating-addiction-drug-manufacturer-alkermes. live.
  125. Web site: Office of the FDA Commissioner. 24 March 2020. FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug. live. 29 December 2021. Food and Drug Administration. en. 29 December 2021. https://web.archive.org/web/20211229153437/https://www.fda.gov/news-events/press-announcements/fda-issues-warning-letter-not-including-most-serious-risks-advertisement-medication-assisted.
  126. Web site: Letter to Tom Price . May 2017 . 11 June 2017 . live . https://web.archive.org/web/20170625103407/http://www.documentcloud.org/documents/3723472-Tom-Price-Letter-Re-MAT.html . 25 June 2017 .
  127. News: Seizing on Opioid Crisis, a Drug Maker Lobbies Hard for Its Product . . 11 June 2017 . 11 June 2017 . Advertising for Vivitrol on a subway car in Brooklyn last month. Marketing for the drug has shifted into high gear. . Goodnough A, Zernike K . live . https://web.archive.org/web/20170611133547/https://www.nytimes.com/2017/06/11/health/vivitrol-drug-opioid-addiction.html . 11 June 2017 .
  128. Book: Simeon D, Abugel J . Feeling Unreal: Depersonalization Disorder and the Loss of the Self. 10 October 2008. Oxford University Press. 978-0-19-976635-2. 166–. 4 October 2016. 15 February 2017. https://web.archive.org/web/20170215043741/https://books.google.com/books?id=ONLyq-mVLuIC&pg=PA166. live.
  129. Book: Lanius UF, Paulsen SL, Corrigan FM . Neurobiology and Treatment of Traumatic Dissociation: Towards an Embodied Self . 13 May 2014 . Springer Publishing Company . 978-0-8261-0632-2 . 489– . 4 October 2016 . 15 February 2017 . https://web.archive.org/web/20170215044041/https://books.google.com/books?id=0i-FAwAAQBAJ&pg=PA489 . live .
  130. Sierra M . Depersonalization disorder: pharmacological approaches . Expert Review of Neurotherapeutics . 8 . 1 . 19–26 . January 2008 . 18088198 . 10.1586/14737175.8.1.19 . 22180718 .
  131. Web site: Novella S . 5 May 2010. Low Dose Naltrexone – Bogus or Cutting Edge Science?. live. https://web.archive.org/web/20110708043917/http://www.sciencebasedmedicine.org/index.php/low-dose-naltrexone-bogus-or-cutting-edge-science/. 8 July 2011. 5 July 2011. Science-Based Medicine.
  132. Web site: Low-Dose Naltrexone. 12 May 2014. National MS Society. 13 May 2014. https://web.archive.org/web/20140513044442/http://www.nationalmssociety.org/Treating-MS/Complementary-Alternative-Medicines/Low-Dose-Naltrexone. live.
  133. Web site: Novella S . Steven Novella. 5 May 2010. Low Dose Naltrexone – Bogus or Cutting Edge Science?. 5 July 2011. 8 July 2011. https://web.archive.org/web/20110708043917/http://www.sciencebasedmedicine.org/index.php/low-dose-naltrexone-bogus-or-cutting-edge-science/. live.
  134. Web site: Bowling AC . Low-dose naltrexone (LDN) The "411" on LDN . dead . https://web.archive.org/web/20090929054506/http://www.nationalmssociety.org/multimedia-library/momentum-magazine/back-issues/momentum-spring-09/download.aspx?id=5587. 29 September 2009. 6 July 2011. National Multiple Sclerosis Society .
  135. News: Addiction drug shows promise lifting long COVID brain fog, fatigue . Reuters . 18 October 2022 . Steenhuysen J . 19 October 2022 . 19 October 2022 . https://web.archive.org/web/20221019171516/https://www.reuters.com/business/healthcare-pharmaceuticals/addiction-drug-shows-promise-lifting-long-covid-brain-fog-fatigue-2022-10-18/ . live .
  136. 10.1007/BF02684958 . Effects of naltrexone on self-injury, stereotypy, and social behavior of adults with developmental disabilities . Journal of Developmental and Physical Disabilities . 7 . 2 . 137–46 . 1995 . Smith SG, Gupta KK, Smith SH . 144215400 .
  137. News: The Reporter . Manley C . 20 March 1998 . Self-injuries may have biochemical base: study . live . https://web.archive.org/web/20090105011250/http://www.mc.vanderbilt.edu/reporter/index.html?ID=461 . 5 January 2009 .
  138. Grant JE, Kim SW, Odlaug BL . A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania . Biological Psychiatry . 65 . 7 . 600–606 . April 2009 . 19217077 . 10.1016/j.biopsych.2008.11.022 . 22992128 .
  139. Kim SW, Grant JE, Adson DE, Shin YC . Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling . Biological Psychiatry . 49 . 11 . 914–921 . June 2001 . 11377409 . 10.1016/S0006-3223(01)01079-4 . 22134798 .
  140. Bostwick JM, Bucci JA . Internet sex addiction treated with naltrexone . Mayo Clinic Proceedings . 83 . 2 . 226–230 . February 2008 . 18241634 . 10.4065/83.2.226 . free .
  141. Vignau J, Karila L, Costisella O, Canva V . [Hepatitis C, interferon a and depression: main physiopathologic hypothesis] . fr . L'Encéphale . 31 . 3 . 349–357 . 2005 . 16142050 . 10.1016/s0013-7006(05)82400-5 . Hepatitis C, interferon a and depression: main physiopathologic hypothesis . .
  142. Małyszczak K, Inglot M, Pawłowski T, Czarnecki M, Rymer W, Kiejna A . [Neuropsychiatric symptoms related to interferon alpha] ]. pl . Psychiatria Polska . 40 . 4 . 787–797 . 2006 . 17068950 . live . Neuropsychiatric symptoms related to interferon alpha . https://web.archive.org/web/20170202010519/http://www.psychiatriapsychoterapia.pl/?a=articles_show&id=459 . 2 February 2017 .
  143. Book: Campbell ND . 28 March 2013 . "Why Can't They Stop?" A Highly Public Misunderstanding of Science . 238–262 . Duke University Press . 10.1215/9780822395874-010 . 978-0-8223-5350-8 . 20 December 2020 . 14 June 2022 . https://web.archive.org/web/20220614045524/https://read.dukeupress.edu/books/book/1700/chapter-abstract/180902/Why-Can-t-They-Stop-A-Highly-Public?redirectedFrom=fulltext . live .
  144. Vrecko S . 1 June 2009. Therapeutic Justice in Drug Courts: Crime, Punishment and Societies of Control . Science as Culture. 18. 2. 217–232 . 10.1080/09505430902885623 . 144197523 .
  145. Aleksanyan J . 9 May 2020. Governing beyond the closet: Remaking stigma, identity, and sexual behavior in a post-disciplinary rehab . Ethnography. 23 . 4 . en. 516–538 . 10.1177/1466138120923702 . 218936388 .
  146. Malandain L, Blanc JV, Ferreri F, Thibaut F . Pharmacotherapy of Sexual Addiction . Current Psychiatry Reports . 22 . 6 . 30 . May 2020 . 32377953 . 10.1007/s11920-020-01153-4 . 218527367 . 6 January 2023 . 6 January 2023 . https://web.archive.org/web/20230106174837/https://hal.sorbonne-universite.fr/hal-02880933/file/Pharmacotherapy%20of%20Sexual%20Addiction.pdf . live .
  147. Herron, Abigail J., Brennan, Tim K. eds. ASAM Essentials of Addiction Medicine, The. 3rd Edition. Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103 USA:Lippincott Williams & Wilkins; 2020.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Naltrexone".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.